Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease-Reference-Cited by-同舟云学术

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease

Published:2021-09 Issue: Volume:Volume 15 Page:3997-4009
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Fraile Julia M,Palliyil Soumya,Barelle Caroline J,Porter Andrew J,Kovaleva Marina

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference47 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

2. GlobalData. Non-alcoholic steatohepatitis (NASH) – opportunity analysis and forecasts to 2029; 2020. Available from: https://store.globaldata.com/report/gdhc113poa–non-alcoholic-steatohepatitis-nash-opportunity-analysis-and-forecasts-to-2029/. Accessed May 28, 2021.

3. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

4. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

5. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy;Frontiers in Cell and Developmental Biology;2024-09-11

2. Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH;Journal of Medicinal Chemistry;2024-09-02

3. Lipid nanoparticle-mediated hepatocyte delivery of siRNA and silibinin in metabolic dysfunction-associated steatotic liver disease;Journal of Controlled Release;2024-09

4. Patchouli alcohol alleviates metabolic dysfunction-associated steatohepatitis via inhibiting mitochondria-associated endoplasmic reticulum membrane disruption-induced hepatic steatosis and inflammation in rats;International Immunopharmacology;2024-09

5. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression;Journal of Hepatology;2024-09